301221-79-4

Basic information

• Product Name: 2-bromo-1-(1-Boc-piperidin-4-yl)ethanone
• Synonyms: 2-bromo-1-(1-Boc-piperidin-4-yl)ethanone;4-(2-Bromoacetyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester;tert-Butyl 4-(bromoacetyl)piperidine-1-carboxylate;1-Boc-4-(2-broMo-acetyl)-piperidine;4-BroMoacetyl-1-(t-butoxycarbonyl)piperidine;4-(2-BroMo-acetyl)-piperidine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(2-bromoacetyl)
• CAS NO: 301221-79-4
• Molecular Formula: C₁₂H₂₀BrNO₃
• Molecular Weight: 306.1961
• Mol File: 301221-79-4.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 368℃
• Flash Point: 176℃
• Appearance: /
• Density: 1.336
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.47±0.40(Predicted)
• CAS DataBase Reference: 2-bromo-1-(1-Boc-piperidin-4-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-1-(1-Boc-piperidin-4-yl)ethanone(301221-79-4)
• EPA Substance Registry System: 2-bromo-1-(1-Boc-piperidin-4-yl)ethanone(301221-79-4)

Safety Data

• Hazardous Substances Data: 301221-79-4(Hazardous Substances Data)

Usage

General Description

2-bromo-1-(1-Boc-piperidin-4-yl)ethanone, also known as BOC-4-Piperidinone Ethyl Bromo, is a complex organic chemical compound. It belongs to the category of pharmaceutical intermediates. The compound has the molecular formula of C12H19BrN2O3 and a molecular weight of 341.195. This substance is commonly used in the chemical and pharmaceutical industry for research purposes or to create other substances. Its CAS number is 57413-43-1, indicating its classification and registration in the Chemical Abstracts Service, a division of the American Chemical Society. Similar to other chemicals, handling and usage of this compound should be done with care, adhering to safety guidelines to avert unintended reactions or health hazards.

Upstream product

• 206989-61-9 4-acetyl-1-(t-butoxycarbonyl)piperidine 
• 139290-70-3 tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 

Downstream Products

• 690261-84-8 4-(2-amino-thiazol-4-yl)-piperidine-1-carboxylic acid tert-butyl ester 
• 690261-82-6 C₁₃H₂₀N₂O₂S 
• 918884-07-8 4-{2-[4-(4-methanesulfonylphenyl)piperazin-1-yl]acetyl}piperidine-1-carboxylic acid tert-butyl ester 
• 1018326-11-8 4-(4-(2-(4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperidin-1-yl)-2-methoxybenzonitrile 
• 1200575-40-1 3-[1-(cyclohexylacetyl)piperidin-4-yl]-7-[4-(methylsulfonyl)phenyl]-3,4-dihydro-2H-1,4-benzoxazine trifluoroacetate 
• 1200575-36-5 tert-butyl 4-{7-[4-(methylsulfonyl)phenyl]-3,4-dihydro-2H-1,4-benzoxazin-3-yl}-piperidine-1-carboxylate 
• 1200576-30-2 7-[4-(methylsulfonyl)phenyl]-3-piperidin-4-yl-3,4-dihydro-2H-1,4-benzoxazine. 

Relevant articles and documents

Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist

Antagonists of adenosine receptor are under exploration as potential drug candidates for treatment of neurological disorders, depression, certain cancers and potentially used as a cancer immunotherapy. Herein, we describe design and synthesis of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine (6) derivatives. All the compounds were evaluated for A2A AR antagonist activity and displayed encouraging results (IC50 9–300 nM) of A2A AR antagonist binding affinity in biochemical assay. Compound 27 exhibits good activity in A2A AR antagonist cAMP functional assay (IC50 31 nM) and further this compound shows T-cell activation at the IL-2 production assay (EC50 165 nM). Molecular docking studies were carried out to rationalize the observed binding affinity of compound 27.

P2X4 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are P2X4 receptor modulating compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including but not limited to, chronic pain, neuropathy, inflammatory diseases and central nervous system disorders.

NEW GPR119MODULATORS

The application relates to compounds of Formula (Ia): and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomersor N-oxides thereof. The application also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the prophylaxis and treatment of medical conditions relating to disorders of the G-protein- coupled receptor GPR119, such as diabetes, obesity and osteoporosis.